Guselkumab in Patients With Skin of Color: VISIBLE Trial Design

EP: 1.Presentation of and Challenges in Treatment of Psoriasis in Patients With Skin of Color

EP: 2.Social and Cultural Stigma of Psoriasis in Patients With Skin of Color

EP: 3.Communicating With Patients With Psoriasis With Skin of Color

EP: 4.Post-Inflammatory Dyspigmentation in Patients With Skin of Color

EP: 5.Topical Treatments for Psoriasis for Patients With Skin of Color

EP: 6.Traditional Systemic Therapy for Psoriasis for Patients With Skin of Color

Now Viewing

EP: 7.Guselkumab in Patients With Skin of Color: VISIBLE Trial Design

EP: 8.Results of VISIBLE Trial in Patients With Skin of Color

EP: 9.Early Use of Systemic Treatments in Patients With Skin of Color

EP: 10.Data With Biologics in Patients With Skin of Color

EP: 11.Advice for Dermatologists in Treating Psoriasis in Patients With Skin of Color

This is a video synopsis/summary of a panel discussion involving Linda Stein Gold, MD; Mona Shahriari, MD, FAAD; and Seemal Desai, MD.

The conversation focuses on the importance of understanding how different patients respond to treatments for psoriasis, particularly those with varying skin tones. The speakers highlight the need for dedicated clinical trials that include a diverse range of participants, including those with lighter and darker skin tones, to provide a comprehensive understanding of treatment efficacy.

They discuss the VISIBLE study, a groundbreaking trial that evaluated the effectiveness of a drug across different skin tones, from Fitzpatrick type 1 to 6. Historically, clinical trials have lacked representation of patients with skin of color, leading to challenges in translating trial results to the broader population. The VISIBLE study aimed to address this gap by specifically including patients with non-white skin tones.

The trial design included two cohorts: one for traditional moderate to severe plaque psoriasis patients and another focusing on scalp psoriasis, a significant concern for patients with skin of color. The study evaluated the drug's efficacy and safety, with primary endpoints including clearance rates and quality of life impact.

A unique aspect of the trial was the use of colorimetry devices to objectively measure skin color and allow patients to self-identify their Fitzpatrick skin type. This approach ensured a more accurate representation of skin tones in the study population.

Furthermore, the trial incorporated enhanced photography to better evaluate erythema and plaque morphology, particularly important for detecting post-inflammatory hyperpigmentation in darker skin types.

Overall, the VISIBLE study represents a significant advancement in understanding psoriasis treatment in diverse patient populations, providing valuable data to guide future treatment decisions and promote inclusivity in healthcare.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.